A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trial

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Clinical Oncology

• Publication date

  2005-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2005.23.16_SUPPL.3036
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Eribulin efficacy in long responder patients with metastatic breast cancer: A multicentric observational study.

  2025cites this paper
• The therapeutic potential and application of marine alkaloids in treating breast cancer

  2024cites this paper
• Immunomodulatory Effects of Halichondrin Isolated from Marine Sponges and Its Synthetic Analogs in Oncological Applications

  2024cites this paper
• Effectiveness, safety, and impact on quality of life of eribulin‐based therapy in heavily pretreated patients with metastatic breast cancer: A real‐world analysis

  2023cites this paper
• A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer

  2023cites this paper
• Multifarious targets beyond microtubules-role of eribulin in cancer therapy.

  2021cites this paper
• Eribulin in brain metastases of breast cancer: outcomes of the EBRAIM prospective observational trial.

  2021cites this paper
• Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer

  2019cites this paper
• A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer

  2019cites this paper
• Advances in the treatment of soft tissue sarcoma: focus on eribulin

  2018cites this paper
• Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma

  2017cites this paper
• Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas

  2016cites this paper
• Review on the clinical use of eribulin mesylate for the treatment of breast cancer

  2016cites this paper
• Practical experiences with eribulin in patients with metastatic breast cancer

  2016cites this paper
• Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.

  2016cites this paper
• Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survival

  2016cites this paper
• Analysis of initial efficacy results of a new cytotoxic prodrug, CAP7.1, in adults with therapy refractory solid tumours in a phase I clinical trial

  2016cites this paper
• Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy

  2015cites this paper
• Eribulin in Cancer Treatment

  2015influential citation
• Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

  2015cites this paper
• Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9

  2015cites this paper
• Eribulin mesylate in patients with locally advanced unresectable or metastatic breast cancer: results and implications of the clinical trials

  2015cites this paper
• Marine Sponge Derived Eribulin in Preclinical and Clinical Studies for Cancer

  2015cites this paper
• Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice.

  2015cites this paper
• Evidence-driven, patient-specific approaches for optimizing survival prolongation in breast cancer.

  2014cites this paper
• Eribulin: a new-generation antimicrotubule agent in lung cancer therapy.

  2014cites this paper
• Eribulin Mesylate in the management of metastatic breast cancer and other solid cancers: a drug review

  2014cites this paper
• Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors

  2014influential citation
• Activity of eribulin mesylate in heavily pretreated breast cancer granted access via the Cancer Drugs Fund.

  2014cites this paper
• Can eribulin change the treatment algorithm in the management of

  2013cites this paper
• Individualizing treatment to optimize survival outcomes in breast cancer.

  2013cites this paper
• Tumor shrinkage and improved quality of life in a heavily pretreated metastatic breast cancer patient treated with eribulin.

  2013cites this paper
• Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

  2013cites this paper
• New Microtubule Inhibitors in Breast Cancer

  2013cites this paper
• Eribulin mesylate in the treatment of metastatic breast cancer

  2012cites this paper
• Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.

  2012cites this paper
• Mechanism of action , pharmacology , and pharmacokinetics ( PK ) of halichondrins with antitumoral activity Mechanism of action

  2012cites this paper
• Clinical evidence for the role of eribulin mesylate in the treatment of breast cancer

  2012cites this paper
• Potential clinical applications of halichondrins in breast cancer and other neoplasms.

  2012cites this paper
• The ixabepilone eribulin mesylate in the treatment of metastatic breast cancer

  2012cites this paper
• A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer.

  2012cites this paper
• Eribulin -- a review of preclinical and clinical studies.

  2012influential citation
• Eribulin Mesylate for the Treatment of Patients with Refractory Metastatic Breast Cancer: Use of a “Physician's Choice” Control Arm in a Randomized Approval Trial

  2012cites this paper
• A Phase II Study of Halichondrin B Analog Eribulin Mesylate (E7389) in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with a Taxane: A California Cancer Consortium Trial

  2012cites this paper
• A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.

  2012cites this paper
• Eribulin monotherapy in a patient with heavily pretreated metastatic breast cancer: Case study and review of the literature

  2012cites this paper
• MANAGING PATIENTS WITH HEAVILY PRETREATED METASTATIC BREAST CANCER: BALANCING EFFICACY AND SAFETY REVIEWS S1 Chemotherapy in patients with heavily pretreated metastatic breast cancer: overview

  2012cites this paper
• Eribulin: A Novel Cytotoxic Chemotherapy Agent

  2012cites this paper
• Eribulin

  2012cites this paper
• eribulin mesylate in the treatment of metastatic breast cancer

  2012cites this paper
• Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer.

  2011influential citation
• Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer.

  2011cites this paper
• Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: What next?

  2011cites this paper
• eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer

  2011cites this paper
• Eribulin mesylate for the treatment of late-stage breast cancer

  2011influential citation
• Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618

  2011cites this paper
• Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer

  2011cites this paper
• Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

  2011cites this paper
• The Place for Eribulin in the Treatment of Metastatic Breast Cancer

  2011cites this paper
• Eribulin mesylate in patients with refractory cancers: a Phase I study

  2011cites this paper
• Advances in therapy: eribulin improves survival for metastatic breast cancer

  2010cites this paper
• Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.

  2010cites this paper
• Eribulin mesylate for the treatment of breast cancer

  2010cites this paper
• A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

  2009cites this paper
• Novel anti-tubulin cytotoxic agents for breast cancer

  2009cites this paper
• Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins.

  2009cites this paper
• Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

  2009cites this paper
• Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors

  2009cites this paper
• Eribulin: Rediscovering Tubulin as an Anticancer Target

  2009cites this paper
• Epothilones and new analogues of the microtubule modulators in taxane-resistant disease

  2008cites this paper
• Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4

  2008cites this paper
• Investigational Anticancer Agents Targeting the Microtubule

  2008cites this paper
• Microtubule-Stabilizing Agent: Halichondrin B Analog (E7389)

  2007cites this paper
• Rapid Communication SOLICITATION FOR LETTERS OF INTENT Clinical trials Preclinical experiments E7389, Halichondrin B analog (NSC 707389)

  2007influential citation
• Highlights from: the third International Congress on Kidney and Bladder Cancer. Orlando, FL; August 3-6, 2006.

  2006cites this paper
• 2005 Highlights From: The 28th Annual San Antonio Breast Cancer Symposium; San Antonio, TX; December 2005

  2006cites this paper
• Meeting Highlights2005 Highlights From: The 28th Annual San Antonio Breast Cancer Symposium; San Antonio, TX; December 2005

  2006cites this paper
• Biologics: Targets and Therapy Dovepress

  year unknowncites this paper
• Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors Cancer Therapy: Clinical

  year unknowncites this paper